![]() |
市場調查報告書
商品編碼
1963976
下一代成像技術市場-全球產業規模、佔有率、趨勢、機會、預測:按技術、應用、類型、地區和競爭格局分類,2021-2031年Next Imaging Technology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast Segmented By Technique, By Application, By Type, By Region & Competition, 2021-2031F |
||||||
全球新一代成像技術市場預計將從 2025 年的 69.9 億美元成長到 2031 年的 129.5 億美元,複合年成長率達到 10.83%。
下一代成像技術涵蓋了超越傳統2D成像限制的先進視覺化系統,包括四維成像、高光譜遙測和全像顯示等多種模式,並已應用於醫療和工業領域。推動該市場發展的關鍵因素包括醫療領域對精準早期診斷能力的日益成長的需求,以及製造業對自動化、零缺陷品質保證的日益成長的需求。此外,人們對非侵入性醫療干預的偏好不斷增強,也加速了這些高清成像解決方案的普及,與傳統設備相比,這些解決方案具有許多操作優勢。
| 市場概覽 | |
|---|---|
| 預測期 | 2027-2031 |
| 市場規模:2025年 | 69.9億美元 |
| 市場規模:2031年 | 129.5億美元 |
| 複合年成長率:2026-2031年 | 10.83% |
| 成長最快的細分市場 | CMOS影像 |
| 最大的市場 | 北美洲 |
儘管有這些有利條件,市場仍面臨一個重大障礙:這些先進技術需要大量的資本投資,而全球經濟的不確定性加劇了這個挑戰。這種財務壓力可能會減緩技術的普及速度,因為企業會優先考慮必要的維護,而不是升級到高階系統。例如,德國機械設備製造業聯合會(VDMA)機器人與自動化協會預測,到2025年,機器視覺領域的收入將達到31億歐元,這一數字反映了由於投資計畫延遲而導致的停滯和零成長時期。這些經濟逆風凸顯了在謹慎的投資環境下,終端用戶難以證明採用下一代影像技術所帶來的高成本是合理的。
人工智慧 (AI) 和機器學習 (ML) 與診斷影像技術的融合是推動全球下一代成像技術市場發展的主要動力。這些計算技術將標準視覺化轉化為預測分析,從而實現自動異常檢測和即時影像重建。透過將演算法整合到磁振造影 (MRI) 和電腦斷層掃描 (CT) 等影像方式中,製造商正在幫助臨床醫生更快、更準確地解讀複雜的 3D 和 4D 數據,顯著降低診斷錯誤率。監管方面的里程碑事件也印證了演算法輔助方法在臨床實踐中的安全性和有效性,進一步推動了這項技術整合。特別是,美國食品藥物管理局(FDA) 於 2024 年 5 月宣布已核准882 款搭載 AI/ML 技術的醫療設備,凸顯了智慧診斷工具的快速商業化進程。
同時,全球慢性病盛行率的不斷上升和人口老化凸顯了高解析度早期檢測系統的必要性。隨著患者群體的變化,醫療機構正優先採用精準醫療工具,以便早期識別腫瘤和心血管疾病等病症。這些人口結構壓力迫使醫院轉型升級,採用能夠進行體積和高光譜遙測的數位基礎設施,從而高效應對日益成長的患者數量。根據美國癌症協會於2024年1月發布的《2024年癌症事實與數據》報告,預計僅2024年美國就將新增2,001,140例癌症病例,凸顯了先進篩檢技術的重要性。因此,主要產業參與者正從先進診斷領域獲得豐厚的利潤;Olympus Corporation公佈,截至2024年3月31日的會計年度,其內視鏡解決方案業務的收入為6026億日圓。
下一代影像系統所需的巨額資本投入是市場擴張的一大障礙。高光譜遙測和4D成像等先進技術價格高昂,且需要大規模支出,這在經濟波動時期對許多企業來說難以承受。隨著企業預算的縮減,核准通常會優先考慮日常營運維護,而不是購置高成本、無缺陷的視覺化工具,這導致銷售週期延長,部署策略也隨之延遲。
這種財務上的猶豫與整個自動化產業的市場萎縮直接相關。正如德國機械設備製造業聯合會(VDMA)在2025年6月發布的《機器人與自動化》報告所述,由於投資計畫的延遲和地緣政治緊張局勢,預計德國自動化產業整體年收入將下降10%。這項統計數據表明,經濟的不確定性迫使終端用戶凍結資本支出,從而抑制了先進成像技術的發展勢頭,儘管這些技術具有技術優勢。因此,無法證明這些高成本投資能夠即時獲得回報,仍是市場滲透的主要障礙。
向永續的無氦磁振造影(MRI)架構轉型正在重塑市場格局,其關鍵在於解決依賴液態氦帶來的供應鏈脆弱性。傳統掃描器需要數千公升冷卻劑,這使得供應商面臨商品價格波動和冷卻劑洩漏(冷卻劑洩漏)的風險,而後者需要昂貴的排氣基礎設施。透過採用密封式低氦磁鐵技術,醫療機構可以消除這些物流負擔,同時由於系統重量減輕,還能在以前無法安裝的位置進行安裝。飛利浦在2024年11月的新聞稿中進一步強調了業界向營運穩健型基礎設施的轉變,該公司表示,其下一代無氦MRI系統BlueSeal迄今已節省了約275萬公升液氦。
光子計數CT系統的商業化標誌著硬體從基於閃爍體的檢測器向直接轉換感測器的演進。這種架構透過探測單一X光光子提供獨特的頻譜數據,顯著降低電子噪聲,並實現精細結構的清晰成像。與傳統的能量積分檢測器不同,這些平台能夠實現精確的材料解析度,並降低易感患者群體的輻射暴露。為了強調這項先進技術在臨床上的應用,西門子健康保險公司在2024年12月的新聞稿中宣布擴展其光子計數CT產品組合,並確認全球已有超過一百萬名患者接受了使用該公司光子計數技術的掃描。
The Global Next Imaging Technology Market is projected to expand from a valuation of USD 6.99 Billion in 2025 to USD 12.95 Billion by 2031, achieving a Compound Annual Growth Rate (CAGR) of 10.83%. Next Imaging Technology encompasses sophisticated visualization systems that surpass traditional two-dimensional limits, including modalities such as four-dimensional imaging, hyperspectral analysis, and holographic displays utilized in both medical and industrial fields. The primary forces driving this market include the increasing need for precise, early diagnostic capabilities in healthcare and the rising demand for automated, zero-defect quality assurance in manufacturing. Additionally, the growing preference for non-invasive medical interventions accelerates the adoption of these high-fidelity imaging solutions, which offer operational advantages distinct from conventional legacy equipment.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 6.99 Billion |
| Market Size 2031 | USD 12.95 Billion |
| CAGR 2026-2031 | 10.83% |
| Fastest Growing Segment | CMOS Imaging |
| Largest Market | North America |
Despite these positive drivers, the market faces a substantial obstacle due to the significant capital expenditure required for these advanced technologies, a challenge often intensified by global economic instability. This financial pressure can result in slower adoption rates as organizations prioritize essential maintenance over upgrading to premium systems. For instance, the VDMA Robotics + Automation association projected that the machine vision subsector would generate revenues of €3.1 billion in 2025, marking a period of stagnation and zero growth attributed to deferred investment plans. Such economic headwinds underscore the difficulty end-users face in justifying the high costs associated with deploying next-generation imaging during a cautious investment climate.
Market Driver
The incorporation of Artificial Intelligence and Machine Learning into imaging diagnostics acts as a primary engine for the advancement of the Global Next Imaging Technology Market. These computational technologies convert standard visualization into predictive analytics, facilitating automated anomaly detection and real-time image reconstruction. By embedding algorithms into modalities such as MRI and CT, manufacturers empower clinicians to interpret complex 3D and 4D data with greater speed and accuracy, significantly minimizing diagnostic errors. This technological convergence is supported by regulatory milestones confirming the safety and efficacy of algorithmic support in clinical settings; notably, the U.S. Food and Drug Administration reported in May 2024 that it had authorized 882 AI/ML-enabled medical devices, highlighting the rapid commercialization of intelligent diagnostic tools.
Simultaneously, the escalating global prevalence of chronic diseases and an aging population drive the necessity for high-resolution, early-detection systems. As patient demographics shift, healthcare providers are prioritizing precision medicine tools capable of identifying pathologies like oncology and cardiovascular conditions at their nascent stages. This demographic pressure compels hospitals to upgrade from analog to digital infrastructures capable of volumetric and hyperspectral analysis to efficiently manage high patient throughput. According to the American Cancer Society's 'Cancer Facts & Figures 2024' report from January 2024, the United States alone is expected to diagnose 2,001,140 new cancer cases in 2024, underscoring the critical need for advanced screening technologies. Consequently, major industry players are securing substantial financial returns from their advanced diagnostic divisions, with Olympus Corporation reporting revenue of ¥602.6 billion for its Endoscopic Solutions Business for the fiscal year ending March 31, 2024.
Market Challenge
The immense capital investment required for next-generation imaging systems constitutes a critical barrier to market expansion. Advanced modalities, such as hyperspectral analysis and four-dimensional imaging, command premium pricing, necessitating large-scale financial outlays that many organizations find difficult to authorize during periods of economic volatility. When corporate budgets contract, decision-makers typically prioritize operational maintenance over acquiring high-cost, zero-defect visualization tools, leading to lengthened sales cycles and postponed deployment strategies.
This financial hesitation is directly correlated with market contraction across the wider automation landscape. As reported by VDMA Robotics + Automation in June 2025, the broader German automation industry was projected to suffer a 10 percent revenue decline for the year due to postponed investment plans and geopolitical tensions. This statistical downturn illustrates how economic instability forces end-users to freeze capital expenditures, thereby stalling the momentum of advanced imaging technologies despite their technical superiority. Consequently, the inability to justify immediate returns on these expensive investments remains a primary obstacle hampering broader market penetration.
Market Trends
The transition toward sustainable and helium-free MRI architectures is reshaping the market by addressing supply chain vulnerabilities associated with liquid helium reliance. Conventional scanners require thousands of liters of coolant, exposing providers to volatile commodity prices and quench hazards that necessitate expensive venting infrastructure. By adopting sealed, low-helium magnet technology, facilities eliminate these logistical burdens while enabling installation in previously inaccessible locations due to reduced system weight. Validating this industry shift toward operationally resilient infrastructure, Philips reported in a November 2024 press release regarding its next-generation BlueSeal helium-free MRI system that its technology has conserved nearly 2.75 million liters of liquid helium to date.
The commercialization of Photon-Counting Computed Tomography Systems represents a hardware evolution from scintillator-based detectors to direct-conversion sensors. This architecture registers individual X-ray photons to provide intrinsic spectral data, significantly reducing electronic noise and enabling the visualization of minute structures with high clarity. Unlike traditional energy-integrating detectors, these platforms facilitate precise material decomposition and lower radiation dosages for vulnerable patient populations. Underscoring the clinical integration of this advanced modality, Siemens Healthineers confirmed in a December 2024 press release expanding its Photon-Counting CT portfolio that over one million patients worldwide have been scanned using their photon-counting technology.
Report Scope
In this report, the Global Next Imaging Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Next Imaging Technology Market.
Global Next Imaging Technology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: